ClinicalTrials.gg
DrugRead study by study

Sacituzumab govitecan clinical trials

Also written Trodelvy, IMMU-132 and GS-0132.

studies test it
102
open now
54
in phase 3
18
first study started
2012
ClinicalTrials.gov finds 172 studies for sacituzumab govitecan. How that becomes 102 here

Every study that search finds has been read, to see whether and how it gives sacituzumab govitecan. ClinicalTrials.gov counts as of Nov 16, 2026. How drug pages count

  1. 172Found by its intervention search · See all 172 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 140 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
  2. −7
    Mention it without giving it — earlier treatment, a protocol code, a title naming another drug
  3. 165Give sacituzumab govitecan to participants
  4. −17Observe patients on it, or give it outside a trial
  5. −3Use it as a tool: an imaging tracer or a test of drug response
  6. −6Compare another treatment with it
  7. −37Give it beside what is tested
  8. 102Test it: the count on this site

Get an email when these change. Save the sacituzumab govitecan studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
22 Apr 2020 · TRODELVY · BLA 761115 (FDA, Drugs@FDA)
European Union
22 Nov 2021 · Trodelvy · EMEA/H/C/005182 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Sacituzumab Govitecan
58
Sacituzumab Govitecan-hziy
23
Sacituzumab Govitecan (SG)
9
hRS7-SN38 Antibody Drug Conjugate
7
RS7-SN38
7

Brand

Trodelvy
49

Development codes

IMMU-132
33
GS-0132
20
hRS7-SN38
1
RO7445735
1

Studies by the year they started

102 studies that test it; most in 2024 (25)

Studies that test sacituzumab govitecan, by start year
YearStudies
20121
20161
20172
20183
20197
20207
20218
20229
202313
202425
202515
202611

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
21
Phase 2
76
Phase 3
18
Phase 4
1
No phase
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 30 · Other 72

Gilead Sciences (23) · National Cancer Institute (NCI) (6) · M.D. Anderson Cancer Center (3) · Yale University (3) · Hoffmann-La Roche (3) · Massachusetts General Hospital (2) · SWOG Cancer Research Network (2) · University of Kansas Medical Center (2)

Often tested with

Tested in the same studies.

Pembrolizumab (6) · Zimberelimab (5) · Trastuzumab deruxtecan (5) · Enfortumab vedotin (5) · Atezolizumab (4) · Domvanalimab (3) · Carboplatin (3) · Nivolumab (3)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 4 phase 3 studies under way

Sacituzumab govitecan is the comparator. A study of two new drugs counts under both.

  • 1Eribulin · National Cancer Institute (NCI)
  • 1Gemcitabine · National Cancer Institute (NCI)
  • 1Apatinib · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · next primary completion Mar 2031
  • 1Beruzatatug pelitecan · MediLink Therapeutics (Suzhou) Co., Ltd. · next primary completion Dec 2027
  • 1JSKN016 · Jiangsu Alphamab Biopharmaceuticals Co., Ltd · next primary completion Mar 2029
New treatments tested with it · 8 most studied

New when their studies opened, with sacituzumab govitecan beside them; studies of each.

Reaching primary completion within a year · 41, 5 in phase 3

Studies that test sacituzumab govitecan, phase 3 first.

Studies

Open first, then newest update. How each study uses sacituzumab govitecan has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.

Testing it · 102

See all 102 studies that test sacituzumab govitecan →

Behind its US label · 5 — the studies the FDA label of TRODELVY describes

From the Clinical Studies section of TRODELVY (2026-06), as openFDA has it. A study the site does not hold is left out.

Tested on its own · 43 — no other medicine in its arm

Showing 20 of 43. See all 43 →

Tested with established drugs · 13 — they are given beside it
Tested in a combination · 46 — another drug in the study is under test too

Showing 20 of 46. See all 46 →

Beside an established treatment under test · 6 — an approved drug, surgery or radiation is what the study tests

Tested with sacituzumab govitecan: pembrolizumab 3 · Nivolumab 1 · Hydroxychloroquine 1

Beside a new treatment under test · 14 — a new drug, cell therapy or vaccine is what the study tests

New treatments tested with sacituzumab govitecan: zimberelimab 2 · tuvutromstat 1 · zedoresertib 1 · berzosertib 1 · azerutamig 1 · AB928 1 · mocaciclib 1 · PARP1 Inhibitor GS-0201 1

Beside supportive care · 9 — a supportive treatment or test is studied
One option of several · 8 — a test or a strategy chooses among drugs
As the comparator · 6 — what is tested is compared with sacituzumab govitecan
Observed · 17 — patients on it are followed, or it is given outside a trial
As a tool · 3 — an imaging tracer or a test of drug response

Codes

What other systems call sacituzumab govitecan · ClinicalTrials.gg INT000470

  • MeSH (NLM) C000608132sacituzumab govitecanConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) M9BYU8XDQ6SACITUZUMAB GOVITECANConfirmed FDA, NLM, Wikidata
  • RxNorm 2360232One source FDA
  • Wikidata Q23901469sacituzumab govitecanConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C102783Sacituzumab GovitecanOne source FDA
  • DrugBank DB12893One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.

Start the discussion